Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

This article is part of the supplement: Proceedings of the 8th Global Arthritis Research Network (GARN) Meeting and 1st Bio-Rheumatology International Congress (BRIC)

Open Badges Poster presentation

Increased concentration of serum soluble LAG3 in systemic lupus erythematosus

Seri Yu*, Keishi Fujio, Kazuyoshi Ishigaki, Hirofumi Shoda, Tomohisa Okamura, Tanita Noor, Shuji Sumitomo and Kazuhiko Yamamoto

  • * Corresponding author: Seri Yu

Author Affiliations

Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, 113-0033, Japan

For all author emails, please log on.

Arthritis Research & Therapy 2012, 14(Suppl 1):P16  doi:10.1186/ar3617

The electronic version of this article is the complete one and can be found online at:

Published:9 February 2012

© 2012 Yu et al.; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


In systemic lupus erythematosus (SLE), type I interferon and plasmacytoid DCs (pDCs) are supposed to play important roles. However, there are few evidences for pDCs activation in SLE. Murine pDCs are reported to produce soluble LAG3 (sLAG3) upon activation and pDCs are responsible for most of sLAG3 in mice serum [1]. Therefore, serum sLAG3 concentration was examined in SLE and other autoimmune diseases.

Materials and methods

This study enrolled 45 SLE patients who met ACR criteiria. Disease activity was rated using a SLE disease activity index (SLEDAI). sLAG3 concentrations were measured by a quantitative sandwich enzyme immunoassay [2].


The ratio of sLAG3 concentration in SLE to control was 3.10+/-1.05, PM/DM to control was 1.04+/-0.08, and RA to control was 0.77+/-0.14. In addition, sLAG3 concentrations showed a significant correlation with SLEDAI. Interestingly, elevation of sLAG3 was observed even in patients with SLEDAI = 0. These results suggested that sLAG3 could be a specific and novel marker for SLE.


sLAG3 can be a novel marker for SLE. sLAG3 in sera of SLE patient may reflect the activation of pDCs. Because sLAG3 shows adjuvant effect when combined with active immunization [3], sLAG3 may contribute to the exacerbation of lupus. The association between elevated sLAG3, type I interferon signature and activation of pDCs should be investigated further.

thumbnailFigure 1. sLAG3 concentrations in SLE and other autoimmune diseases measured by ELISA.